Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease

Bone Marrow Transplantation volume 33, pages 1–7 (2004)Cite this article

Summary:

Transfusion-associated graft-versus-host disease (TA-GVHD) is a serious complication of blood component transfusion therapy. Currently, cellular blood components for patients recognized at risk for TA-GVHD are irradiated prior to transfusion in order to prevent this complication. Considerable progress has been made in elucidating the pathophysiology of this highly morbid complication, but questions as to which patients are at risk and what is the most robust technology to prevent TA-GVHD remain. As new technologies for inactivating or modulating leukocyte function are introduced, the question of how to evaluate these technologies becomes relevant. Over the past two decades, a number of research groups have explored technology to inactivate infectious pathogens and leukocytes contaminating cellular blood components. Few clinicians have an in-depth understanding of the methods or the criteria for selection of how to approach new technologies for leukocyte inactivation with potential to replace current methods. This mini review focuses on the salient aspects of current and evolving technology for prevention of TA-GVHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Anderson KC, Weinstein HJ . Transfusion-associated graft-versus-host disease. N Eng J Med 1990; 323: 315–321.

    Article  CAS  Google Scholar 

  2. Ohto H, Anderson KC . Survey of transfusion-associated graft-versus-host disease in immunocompetent recipients. Transfusion Med Rev 1996; 10: 31–43.

    Article  CAS  Google Scholar 

  3. Hathaway WE, Githens JA, Blackburn JR et al. Aplastic anemia, histiocytosis, and erythroderma in immunologically deficient children. N Engl J Med 1965; 273: 953.

    Article  CAS  Google Scholar 

  4. vonFliedner V, Higby DJ, Kim U . Graft-versus-host reaction following blood product transfusion. Am J Med 1972; 72: 951.

    Article  Google Scholar 

  5. Brubaker DB . Immunopathogenic mechanims of post-transfusion graft versus host disease. Proc Soc Exp Biol Med 1993; 202: 122–147.

    Article  CAS  Google Scholar 

  6. Fearon TC, Luban NLC . Practical dosimetric aspects of blood and blood product irradiation. Transfusion 1986; 26: 457–459.

    Article  CAS  Google Scholar 

  7. Crowley JP, Skrabut EM, Valeri CR . Immunocompetent lymphocytes in previously frozen washed red cells. Vox Sanguinis 1974; 26: 513–517.

    Article  CAS  Google Scholar 

  8. Akahoshi M, Takanashi M, Masuda M . A case of transfusion-associated graft-versus-host disease not prevented by white cell-reduction filters. Transfusion 1992; 32: 169–172.

    Article  CAS  Google Scholar 

  9. Hayashi H, Nishiuchi T, Tamura H . Transfusion-associated graft-versus-host disease caused by leukocyte filtered stored blood. Anesthesiology 1993; 79: 1419–1421.

    Article  CAS  Google Scholar 

  10. CBER F. Gamma Irradiation of Blood and Blood Components: A Pilot Program for Licensing. Food and Drug Administration Center for Biologics Evaluation and Research (CBER): Rockville, 2000, 1–12.

  11. Wieding JU, Vehmeyer K, Riggert J et al. Fresh–frozen plasma contains proliferable stem cells. Transfusion 1993; 33 (Suppl 9S): 53S.

    Google Scholar 

  12. Sprent J, Anderson RE, Miller JFAP . Radiosensitivity of T and B lymphocytes. II. Effect of radiation on response of T cells to alloantigens. Eur J Immunol 1974; 4: 204.

    Article  CAS  Google Scholar 

  13. Dobrynski W, Thibodeau S, Truitt RL et al. Third-party-mediated graft rejection and graft-versus-host disease after T-cell-depleted bone marrow transplantation as demonstrated by hypervariable DNA probes and HLA-DR polymorphism. Blood 1989; 74: 2285.

    Google Scholar 

  14. Sproul AM, Chalmers EA, Mills KI . Third part mediated graft rejection despite irradiation of blood products. Br J Haematol 1993; 80: 251–252.

    Article  Google Scholar 

  15. Lowenthal RM, Challis DR, Griffiths AE . Transfusion-associated graft-versus-host disease: report of an occurrence following administration of irradiated blood. Transfusion 1993; 33: 524–529.

    Article  CAS  Google Scholar 

  16. Barbara J . The rationale for pathogen inactivation treatment of platelet components – introduction. Sem Hematol 2001; 38 (Suppl 11): 1–3.

    Article  CAS  Google Scholar 

  17. Rosen NR, Wiedner JG, Boldt HD et al. Prevention of transfusion-associated graft-versus-host disease: selection of an adequate dose of gamma irradiation. Transfusion 1993; 33: 125.

    Article  CAS  Google Scholar 

  18. Kanter MH . Transfusion-associated graft-versus-host disease: do transfusions from second-degree relatives pose a greater risk than those from first-degree relatives? Transfusion 1992; 32: 323–327.

    Article  CAS  Google Scholar 

  19. Benson K, Marks AR, Marshall MJ . Fatal graft-versus-host disease associated with transfusions of HLA-matched, HLA homozygous platelets from unrelated donors. Transfusion 1994; 34: 432–437.

    Article  CAS  Google Scholar 

  20. Lee TH, Paglieroni T, Ohto H, Holland PV, Busch MP . Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: frequent long-term microchimerism in severe trauma patients. Blood 1999; 93: 3127–3139.

    CAS  Google Scholar 

  21. Rosen NR, Wiedner JG, Bold HD . Prevention of transfusion-associated graft-versus-host disease: selection of an adequate dose of gamma irradiation. Transfusion 1993; 33: 125–127.

    Article  CAS  Google Scholar 

  22. Luban NLC . Prevention of transfusion-associated graft-versus-host disease by inactivation of T cells in platelet components. Sem Hematol 2001; 38 (Suppl 11): 34–45.

    Article  CAS  Google Scholar 

  23. Pelszynski MM, Moroff G, Luban NLC et al. Effect of gamma irradiation on T-cell inactivation as assessed by limiting dilution Analysis: Implications for Preventing transfusion associated graft vs host disease. Blood 1994; 83: 1683.

    CAS  PubMed  Google Scholar 

  24. Seghatchian MJ, Stivala JFA . Effect of 25 Gy gamma irradiation on storage stability of three types of platelet concentrates: a comparative analysis with paired controls and random preparation. Transfusion Sci 1995; 16: 121–129.

    Article  Google Scholar 

  25. Edelson R, Berger C, Gasparro F et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987; 316: 297–303.

    Article  CAS  Google Scholar 

  26. French LE, Alcindor T, Shapiro M et al. Identification of amplified clonal T cell populations in the blood of patients with chronic graft-versus-host disease: positive correlation with response to photopheresis. Bone Marrow Transplant 2002; 30: 509–515.

    Article  CAS  Google Scholar 

  27. Dodd RY, Moroff G, Wagner S et al. Inactivation of viruses in platelet suspensions that retain their in vitro characteristics: comparison of psoralen–ultraviolet A and merocyanine 540-visible light methods. Transfusion 1991; 31: 483–490.

    Article  CAS  Google Scholar 

  28. Lin L, Wiesehahn GP, Morel PA et al. Use of 8-methoxypsoralen and long wavelength ultraviolet radiation for decontamination of platelet concentrates. Blood 1989; 74: 517–525.

    CAS  PubMed  Google Scholar 

  29. Lin L, Londe H, Hanson CV et al. Psoralen photochemical inactivation of cell-free HIV-1 in platelet concentrates is correlated with the inhibition of reverse transcription using an RT/PCR assay. Blood 1992; 80 (Suppl 1): 223a.

    Google Scholar 

  30. Wagner SJ, Bardossy L, Moroff G et al. Assessment of the hemostatic effectiveness of human platelets treated with aminomethyltrimethyl psoralen and UVA light using a rabbit ear bleeding time technique. Blood 1993; 82: 3489–3492.

    CAS  PubMed  Google Scholar 

  31. Lin L, Cook DN, Wiesehahn GP et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997; 37: 423–435.

    Article  CAS  Google Scholar 

  32. van Rhenen DJ, Vermeij J, Mayaudon V et al. In vitro platelet function of S59 photochemically treated platelet concentrates. Transfusion 1997; 37 (Suppl): 14s.

    Google Scholar 

  33. Grass JA, Hei DJ, Metchette K et al. Inactivation of leukocytes in platelet concentrates by psoralen plus UVA. Blood 1998; 91: 2180–2188.

    CAS  PubMed  Google Scholar 

  34. Hei DJ, Grass J, Lin L et al. Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion 1999; 39: 239–248.

    Article  CAS  Google Scholar 

  35. Grass JA, Wafa T, Reames A et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999; 93: 3140–3147.

    CAS  PubMed  Google Scholar 

  36. Knutson F, Alfonso R, Dupuis K et al. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sanguinis 2000; 78: 209–216.

    Article  CAS  Google Scholar 

  37. vanRhenen D, Gulliksson H, Cazenave JP et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101: 2426–2433.

    Article  CAS  Google Scholar 

  38. Wollowitz S . Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Sem Hematol 2001; 38 (Suppl 11): 4–11.

    Article  CAS  Google Scholar 

  39. vanRhenen DJ, Vermeij J, Mayaudon V et al. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sanguinis 2000; 79: 206–214.

    Article  CAS  Google Scholar 

  40. Przepiorka D, LeParc GF, Stovall MA et al. Use of irradiated blood components. Am J Clin Pathol 1995; 106: 6.

    Article  Google Scholar 

  41. Fiebig E, Hirschkorn DF, Maino VC et al. Assessment of donor T-cell function in cellular blood components by the CD69 induction assay: effects of storage, gamma irradiation, and photochemical treatment. Transfusion 2000; 40: 761–770.

    Article  CAS  Google Scholar 

  42. Fast LD, DiLeone G, Edson CM et al. PEN 110 treatment funtionally inactivates the PBMNCs present in RBC units: comparison to the effects of exposure to gamma irradiation. Transfusion 2002; 42: 1318–1325.

    Article  CAS  Google Scholar 

  43. Setlow RB, Setlow JK . Effect of radiation on polynucleotides. In: Baldwin ML JL (ed.) Irradiation of Blood Components, Volume: 1–30 AABB Press: Bethesda, 1992.

    Google Scholar 

  44. Ferrara J, Burakoff SJ . The pathophysiology of acute graft vs host disease in a murine bone marrow transplant model. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds). Graft Versus Host Disease: Immunology, Pathophysiology, and Treatment. Marcel Dekker, Inc.: New York, 1990, 9–29.

    Google Scholar 

  45. Fast LD, Valeri CR, Crowley JP . Immune responses to major histocompatibility complex homozygous cells in murine F 1 hybrid recipients: implications for transfusion- associated graft-versus-host disease. Blood 1995; 86: 3090.

    CAS  PubMed  Google Scholar 

  46. Grass J, Delmonte J, Wages D et al. Prevention of transfusion-associated graft vs host disease (TA-GVHD) in immunocompromised mice by photochemical treatment (PCT) of donor T cells. Blood 1997; 90 (Suppl 1): 207a.

    Google Scholar 

  47. Truitt RL, Johnson BD, Hanke C et al. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation. J Immunol 1999; 163: 5145–5156.

    CAS  PubMed  Google Scholar 

  48. Fast LD, DiLeone G, Edson CM et al. Inhibition of murine GVHD by PEN 110 treatment. Transfusion 2002; 42: 1326–1332.

    Article  CAS  Google Scholar 

  49. vanRhenen D, Gulliksson H, Pamphilon D et al. S-59 Helinx photochemically treated platelets(plt) are safe and effective for support of thrombocytopenia: results of the EUROSPRITE Phase 3 trial. Blood 2000; 96: 819a.

    Google Scholar 

  50. Conlan M, Lin JS, Flament J, Lin L, Corash L . INTERCEPT platelets treated with Helinx technology to inactivate T-cells prevented transfusion-associated graft-versus-host disease (TA-GVHD): results of 3 clinical trials. VIII European Congress of the International Society of Blood Transfusion 2003, Istanbul, Turkey International Society of Blood Transfusion, 2003, p 22.

    Google Scholar 

  51. Deeg HJ, Graham TC, Gerhard-Miller L et al. Prevention of transfusion-induced graft-versus-host disease in dogs by ultraviolet irradiation. Blood 1989; 74: 2592–2595.

    CAS  PubMed  Google Scholar 

  52. Lin L, Londe H, Hanson CV et al. Photochemical inactivation of cell-associated human immunodeficiency virus in platelet concentrates. Blood 1993; 82: 292–297.

    CAS  PubMed  Google Scholar 

  53. Moroff G, Wagner S, Benade L et al. Factors influencing virus inactivation and retention of platelet properties following treatment with aminomethyltrimethylpsoralen and ultraviolet. A light. Blood Cells 1992; 18: 43–56.

    CAS  PubMed  Google Scholar 

  54. Prodouz KN, Lytle CD, Keville EA et al. Inhibition by albumin of merocyanine 540-mediated photosensitization of platelets and viruses. Transfusion 1991; 31: 415–422.

    Article  CAS  Google Scholar 

  55. Rywkin S, Ben-Hur E, Malik Z et al. New phthalocyanines for photodynamic virus inactivation in red blood cell concentrates. Photochem Photobiol 1994; 60: 165–170.

    Article  CAS  Google Scholar 

  56. Skripchenko AA, Wagner SJ . Inactivation of WBCs in RBC suspensions by photoactive phenothiazine dyes: comparison of dimethylmethylene blue and MB. Transfusion 2000; 40: 968–975.

    Article  CAS  Google Scholar 

  57. Hanson D, Propst M, Dupuis K et al. High titer leukocyte inactivation in INTERCEPT red blood cells (RBC). Transfusion Clin Biol 2001; 8 (Suppl 1): 45s.

    Google Scholar 

  58. Goodrich RP . The use of riboflavin for the inactivation of pathogens in blood products. Vox Sanguinis 2000; 78 (Suppl 2): 211–215.

    CAS  PubMed  Google Scholar 

  59. Mohr H, Redecker-Klein A . Inactivation of pathogens in platelet concentrates by uisng a two-step procedure. Vox Sanguinis 2003; 84: 96–104.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cerus Corporation, Concord, USA

    L Corash & L Lin

  2. The University of California, San Francisco, USA

    L Corash

Authors
  1. L Corash
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Corash.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Corash, L., Lin, L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 33, 1–7 (2004). https://doi.org/10.1038/sj.bmt.1704284

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704284

Keywords

This article is cited by

Search

Advanced search

Quick links